InsiderTrades

Form 4 for LXEO Lexeo Therapeutics, Inc.

Accepted 2023-11-09 00:00:00 ET · period of report 2023-11-07 · accession 0001209191-23-054913 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DM 2023-11-09 2023-11-07 LXEO Paster Anne-Mari 10% C - Cnv Deriv — +1.70M 1.70M New —
D 2023-11-09 2023-11-07 LXEO Paster Anne-Mari 10% P - Purchase $11.00 +454.5K 2.16M +27% +$5.00M
DM 2023-11-09 2023-11-07 LXEO Paster Anne-Mari 10% C - Cnv Deriv — -17.62M 0 -100% —

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2023-11-07 C A 1,415,865 — 1,415,865 D — — (F1) Upon the closing of the Issuer's initial public offering, each share of Series A convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-10.594230 basis. The shares had no expiration date.
2 Common Common Stock 2023-11-07 C A 287,213 — 1,703,078 D — — (F2) Upon the closing of the Issuer's initial public offering, each share of Series B convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-9.106601 basis, which reflects an anti-dilution adjustment to the conversion ratio pursuant to a provision of the Series B convertible preferred stock based on the pricing of the initial public offering (as described in the Reporting Person's Form 3). The shares had no expiration date.
3 Common Common Stock 2023-11-07 P A 454,545 $11.00 2,157,623 D — —
4 Derivative Series B convertible preferred stock 2023-11-07 C D 2,615,533 — 0 D — · — to — 287,213 Common Stock (F2) Upon the closing of the Issuer's initial public offering, each share of Series B convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-9.106601 basis, which reflects an anti-dilution adjustment to the conversion ratio pursuant to a provision of the Series B convertible preferred stock based on the pricing of the initial public offering (as described in the Reporting Person's Form 3). The shares had no expiration date.
5 Derivative Series A convertible preferred stock 2023-11-07 C D 14,999,999 — 0 D — · — to — 1,415,865 Common Stock (F1) Upon the closing of the Issuer's initial public offering, each share of Series A convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-10.594230 basis. The shares had no expiration date.